Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.
复制标题
DOI：
10.1177/2324709617728528
复制
发表时间：
2017-07
影响因子：
1.2
通讯作者：
Moore TB
中科院分区：
文献类型：
--
作者：
Upadhyay SY;De Oliveira SN;Moore TB
The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosuppressive drugs after HSCT is crucial. This case report demonstrates that rapamycin and GVL represent a viable medical strategy for the management of pediatric patients with JMML who relapse following status post-HSCT.
